Skip to main content

Post-Market Study to Assess iTind Safety in Comparison to UroLift

Recruiting · Not applicable · NCT04757116

Conditions: Benign Prostatic Hyperplasia (BPH)

At a glance

Research payments reported, 2025
$1.5M
U.S. investigators named
16
Sites paid
16
Planned or actual enrollment
256

About the trial

Sponsor
Olympus Corporation of the Americas (with Olympus Europe SE & Co. KG)
Tested
iTind (device), UroLift (procedure)
Dates
Started 2022-09-26; completion 2030-05-31
Results posted
Not yet

The study objective is to evaluate the efficacy and safety of the iTind device compared to UroLift.

From ClinicalTrials.gov, last updated 2026-09-29. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Olympus Corporation of The Americas reported $1.5M in research payments for this study in 2025 (70 payments).

Products named: Itind System

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • The Conrad Pearson Clinic $411,392
  • Potomac Urology Center $364,954
  • The Urology Place $124,046
  • Pacific West Urology $94,148
  • The Feinstein Institutes for Medical Research $79,088
  • Midtown Urology Associates PA $74,961
  • Adult & Pediatric Urology, PC $74,461
  • Golden State Urology $63,180
  • Mayo Clinic Hospital, AZ $48,855
  • Urology Associates of Central California $31,196
  • Arizona Urology Specialists $30,809
  • Louisiana Veterans Research & Education Corporation $26,760
  • Northshore University Healthsystem - Evanston Hospital, IL $18,036
  • Minnesota Urology PA $13,530
  • Northwestern University $10,810
  • Carolina Urologic Research Center $8,000

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.